Nuo Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.3M | $1.4M | $608.5K | $112.3K | $0 | $0 | $146.2K | $1.4M |
| Cost of Revenue | $1.1M | $302.8K | $126.1K | $19.2K | $0 | $0 | $114.6K | $163.0K |
| Gross Profit | $2.2M | $1.1M | $482.4K | $93.0K | $0 | $0 | $31.6K | $1.2M |
| Gross Margin | 66.9% | 77.8% | 79.3% | 82.9% | — | — | 21.6% | 88.1% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | $0 | $0 | $181.2K | $576.2K |
| SG&A Expense | $4.7M | $3.5M | $3.7M | $3.4M | $90.7K | $378.1K | $789.1K | $2.0M |
| Operating Income | $-2.5M | $-2.5M | $-3.2M | $-3.3M | $-90.7K | $-378.1K | $-969.2K | $-1.5M |
| Operating Margin | -76.0% | -180.0% | -520.6% | -2,958.2% | — | — | -663.0% | -109.8% |
| Interest Expense | — | — | — | — | $0 | $48.4K | $221.5K | $38.9K |
| Pretax Income | $-2.5M | $-2.3M | $-3.2M | $-3.2M | $-90.7K | $-90.9K | $-1.2M | $-1.5M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net Income | $-2.5M | $-2.3M | $-3.2M | $-3.2M | $-90.7K | $-90.9K | $-1.2M | $-1.5M |
| Net Margin | -75.8% | -170.2% | -521.2% | -2,825.6% | — | — | -817.4% | -112.5% |
| EPS (Basic) | $-0.05 | $-0.05 | $-0.08 | $-0.08 | $-0.03 | $0.30 | $-0.05 | $-0.07 |
| EPS (Diluted) | — | — | — | — | $-0.03 | $0.27 | $-0.05 | $-0.07 |
| Shares Outstanding (Basic) | 47.3M | 45.4M | 42.1M | 40.0M | 30.3M | 25.7M | 23.7M | 23.3M |
| Shares Outstanding (Diluted) | 47.3M | 45.4M | 42.1M | 40.0M | 30.3M | 27.3M | 23.7M | 23.3M |
| Dividends Per Share | — | — | — | — | — | — | — | — |